Tango Therapeutics, Inc. (TNGX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenue | 3,181 | 5,392 | 11,607 | |
| Research and development | 32,807 | 36,442 | 33,263 | |
| General and administrative | 11,341 | 11,480 | 11,222 | |
| Total operating expenses | 44,148 | 47,922 | 44,485 | |
| Loss from operations | -40,967 | -42,530 | -32,878 | |
| Other income, net | 910 | 1,074 | 1,956 | |
| Interest income | 1,239 | 1,614 | 1,809 | |
| Total other income, net | 2,149 | 2,688 | 3,765 | |
| Loss before income taxes | -38,818 | -39,842 | -29,113 | |
| Provision for income taxes | 35 | 34 | 54 | |
| Net loss | -38,853 | -39,876 | -29,167 | |
| Net loss per common share - basic | -0.35 | -0.36 | -0.27 | |
| Net loss per common share - diluted | -0.35 | -0.36 | -0.27 | |
| Weighted-average common stock outstanding - basic | 110,540,836 | 110,301,256 | 108,507,390 | |
| Weighted-average common stock outstanding - diluted | 110,540,836 | 110,301,256 | 108,507,390 | |